Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2
| Autor: | Eri Morimoto, Yoshitake Hayashi, Soo Ki Kim, Kayo Sugimoto, Soo Ryang Kim, Yasuhito Tanaka, Masatoshi Kudo, Yoshihiko Yano, Airi Kato, Susumu Imoto, Chi Wan Kim, Mana Kobayashi |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Liver Cirrhosis Male medicine.medical_specialty Genotype Sofosbuvir Hepacivirus Hepatitis C virus medicine.disease_cause Antiviral Agents Gastroenterology Polyethylene Glycols Hemoglobins 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pegylated interferon Internal medicine Ribavirin Humans Medicine Pyrophosphatases Aged Drug Carriers biology business.industry Age Factors General Medicine Hepatitis C Chronic Middle Aged biology.organism_classification Virology Discontinuation Treatment Outcome chemistry 030220 oncology & carcinogenesis Drug Therapy Combination Female 030211 gastroenterology & hepatology Interferons ITPA Safety business medicine.drug |
| Zdroj: | Digestive Diseases. 34:627-631 |
| ISSN: | 1421-9875 0257-2753 |
| DOI: | 10.1159/000448823 |
| Popis: | Objectives: The efficacy of sofosbuvir plus ribavirin (RBV) treatment for hepatitis C virus (HCV) genotype 2 focusing on virological response was compared with that of pegylated interferon (peg-IFN) plus RBV treatment. Safety of the former focusing on the decline in hemoglobin levels was compared with that of the latter and assessed in terms of age and inosine triphosphatase (ITPA). Methods: Patients (n = 17) receiving sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV diagnosed with chronic HCV genotype 2 were enrolled in this study, and the efficacy and safety of both treatments were assessed. Results: Rapid virological response was attained with sofosbuvir plus RBV treatment compared with peg-IFN plus RBV treatment. All patients under sofosbuvir plus RBV treatment achieved end-of-treatment response compared with 70% who sustained viral response under the peg-IFN plus RBV treatment, with the former demonstrating greater virological response. The decline in hemoglobin levels under the former treatment was greater than that under the latter and in patients over 65 years of age with ITPA gene major. Conclusion: Efficacy and safety of sofosbuvir plus RBV treatment were clearly demonstrated compared with those of peg-IFN plus RBV treatment. The decline in hemoglobin levels was not related to the discontinuation of the former treatment, irrespective of age or the effect of the ITPA gene. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|